Frequently Asked Questions
What is the 52-week range for CGTX?
The 52-week high is $2.05 and the 52-week low is $0.5501.
What is the P/E ratio for CGTX?
The P/E ratio data is currently unavailable.
What is the dividend yield for CGTX?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -50.17%.
What is the Net Profit Margin?
Net Margin data is currently unavailable.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 3.48.
Analyst Recommendation Trends
Wall Street analyst consensus for CGTX over the last few months:
Latest CGTX News
Cognition Therapeutics Schedules a Type C Meeting with FDA to Align on Endpoints for Phase 3 Trial of Zervimesine (CT1812) in DLB
October 20th Meeting with the Division of Neurology Expected to Define Endpoint for Phase 3PURCHASE, N.Y., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders, (the “Company” or “Cognition”), announced that a Type C meeting with the U.S. Food and Drug Administration (FDA) Division of Neurology has been scheduled for October 20, 2026. The objective
Cognition Therapeutics' Type C Meeting With FDA To Take Place Oct. 20 For Planned Trial Of Zervimesine
Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders, (the "Company" or "Cognition"),
Cognition Therapeutics to Present at H.C. Wainwright Global Investment Conference
PURCHASE, N.Y., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the Company’s president and CEO, Lisa Ricciardi intends to present at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15, 2026 at 2:30 p.m. Eastern Time. During her presentation, Ms. Ricciardi will discuss progress on the Company’s development of zervimesine for Alzheimer
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-06-17 | BIOS Fund II QP, LP | +25,000 | - | - |
| 2026-06-17 | Khattar Jack A. | +25,000 | - | - |
| 2026-06-17 | Monia Brett P | +25,000 | - | - |
| 2026-06-17 | Wallace Peggy | +25,000 | - | - |
| 2026-06-17 | RICHSTONE ELLEN B | +25,000 | - | - |
| 2026-05-01 | Doyle John Brendan | -8,567 | $1.28 | $10,966 |
| 2026-04-16 | Doyle John Brendan | +10,000 | $1.13 | $11,300 |
| 2026-04-16 | Caggiano Anthony | +10,000 | $1.11 | $11,100 |
| 2026-04-16 | Ricciardi Lisa | +9,175 | $1.1 | $10,093 |
| 2026-02-15 | Doyle John Brendan | -1,560 | $1.12 | $1,747 |
| 2026-02-15 | Caggiano Anthony | -4,680 | $1.12 | $5,242 |
| 2026-02-15 | Ricciardi Lisa | -5,850 | $1.12 | $6,552 |
| 2026-02-04 | Doyle John Brendan | -26,921 | $1.03 | $27,729 |
| 2026-02-04 | Caggiano Anthony | -26,919 | $1.03 | $27,727 |
| 2026-02-04 | Ricciardi Lisa | -51,704 | $1.03 | $53,255 |
| 2026-02-03 | Doyle John Brendan | +200,000 | - | - |
| 2026-02-03 | Caggiano Anthony | -11,488 | $1.12 | $12,867 |
| 2026-02-03 | Caggiano Anthony | +400,000 | - | - |
| 2026-02-03 | Ricciardi Lisa | -26,036 | $1.12 | $29,160 |
| 2026-02-03 | Ricciardi Lisa | +800,000 | - | - |
| 2025-12-18 | Caggiano Anthony | -20,280 | $1.5 | $30,420 |
| 2025-12-18 | Caggiano Anthony | +65,000 | - | - |
| 2025-12-18 | Doyle John Brendan | -9,360 | $1.5 | $14,040 |
| 2025-12-18 | Doyle John Brendan | +30,000 | - | - |
| 2025-12-18 | Ricciardi Lisa | -23,400 | $1.5 | $35,100 |
| 2025-12-18 | Ricciardi Lisa | +75,000 | - | - |